Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients (UTI-RTOM-NPC)

  • STATUS
    Recruiting
  • days left to enroll
    28
  • participants needed
    176
  • sponsor
    Sun Yat-sen University
Updated on 26 February 2022

Summary

This is a phase 3, open-label, multicenter, randomized controlled phase III clinical trial. The purpose of this study is to evaluate the efficacy of ulinastatin, a kind of protease inhibitor, in the treatment of radiation-induced acute oral mucositis in localregionally advanced nasopharyngeal carcinoma(NPC) patients treated with concurrent chemoradiotherapy(CCRT). To Explore a new and efficient way to reduce the incidence and severity of radiation-induced acute oral mucositis.

Description

Radiation-induced acute oral mucositis (RTOM) in Nasopharyngeal Carcinoma (NPC) patients treat with concurrent chemoradiotherapy (CCRT) is common. Currently, there is no effective treatment for RTOM. Ulinastatin, is a kind of natural anti-inflammatory substance. And this substance is insufficient when the body's inflammatory response is strongly. There are a series of studies have confirmed the efficacy and safety of ulinastatin in the treatment of body's inflammatory response. From the observation of our previous clinical practice, we found that ulinastatin can relieve the severity of RTOM. The present study is undertaken to evaluate the efficacy of ulinastatin in the treatment of RTOM in localregionally advanced NPC patients treated with CCRT.

Details
Condition Oral Mucositis (Ulcerative) Due to Radiation
Treatment cisplatin, Intensity Modulated Radiation Therapy, ulinastatin
Clinical Study IdentifierNCT03387774
SponsorSun Yat-sen University
Last Modified on26 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Newly histologic diagnosis of nasopharyngeal carcinoma without distant metastasis
Clinical stage III~IVa( UICC (Union International Against Cancer) /AJCC (American Joint Committee on Cancer) TNM staging system 8th edition)
Karnofsky Performance Status Scale between 80-100
WBC count ≥ 4×109/L,neutrophil differential count≥ 1.5×109/L,Hemoglobin ≥ 90g/L, platelet count ≥ 100×109/L
ALT or AST ≤2.5×ULN,bilirubin ≤2.5×ULN,Serum creatinine ≤1.5×ULN or Serum creatinine clearance≥60ml/min
Sign the informed consent

Exclusion Criteria

Angle of sexual squamous cell carcinomas and basal cell layout, squamous cell carcinomas
Younger than 18 years old or older than 70 years old
Pregnancy or lactation
Severe cerebrovascular disease/canker/psychosis/uncontrolled diabetes
Have suffered from other tumor or now suffering from other tumor
Have suffered from oral diseases or salivary gland diseases or mow suffering from oral diseases or salivary gland diseases
Refuse to give up smoking/drinking/betel chewing
suffering from other active infection diseases and in need of treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note